A medicinal cannabis trial has had “overwhelmingly positive” early results for 60% of patients who could not relieve their pain using conventional forms of care.
The treatment should be widely available for prescription next year.
The French trial of medicinal cannabis has involved the participation of more than 3,000 patients since it started in 2021.
A government decree extended the trial, which was set to run until April, until the end of this year, and ANSM (the national agency for the safety of medicines and health products) has announced that treatments will be made available in 2025.
“We have shown that hundreds of healthcare professionals can be trained to prescribe new drugs, but above all we have demonstrated that these treatments are a perfect addition to the arsenal of drugs available to patients who have reached a therapeutic impasse,” Professor Nicolas Authier, chairman of the Temporary scientific committee to monitor experiments with cannabis for medical use (CST), told Le Point.
